Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality, and innovation. This is a particularly important and timely exchange, given the bio-pharmaceutical industry’s need to strengthen trust and confidence — and ultimately the health and well being — of individuals.
Sir Andrew Witty, Chief Executive Officer of GlaxoSmithKline, will open the session with a keynote address on how GlaxoSmithKline’s recent reforms are changing its engagement across different markets worldwide. He will outline new approaches on sales and marketing, transparency of clinical trials data, pricing, and research and development into meeting unmet medical need. His speech comes at a key moment, as the UN Secretary-General’s High-Level Panel on Access to Medicines, on which Sir Witty serves, carries forward its deliberations.
Following Sir Andrew’s presentation, there will be a roundtable conversation that will explore these themes in more depth. The panelists will include: Sir Andrew Witty, Dr. Margaret Hamburg, Foreign Secretary of the Institute of Medicine, and Dr. Ezekiel Emmanuel, Vice Provost for Global Initiatives and Chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania. J. Stephen Morrison, Senior Vice President and Director of the CSIS Global Health Policy Center will moderate. We do hope you can attend!
